In the sphere of weight management, recent developments in France are generating significant interest<\/strong> among healthcare professionals and patients alike. Historically, only renewals of prescriptions were possible for specific weight loss treatments. However, this is now poised to change as the French government moves towards allowing general practitioners (GPs)<\/strong> to prescribe certain anti-obesity<\/em> medications.<\/p>\n Since their introduction to the market in 2024, two significant treatments have been tightly regulated. Currently, only specialists in endocrinology, diabetology, or nutrition are authorized to prescribe them. This restrictive approach stems from concerns over misuse for cosmetic purposes<\/em>, given these medications’ proven effectiveness in weight loss<\/strong>.<\/p>\n The Agence nationale du m\u00e9dicament<\/strong> (ANSM) is set to initiate procedures that would allow GPs to prescribe these medications. This decision aligns with requests from Catherine Vautrin, the Minister of Health<\/strong>, and Yannick Neuder, the Minister Delegate for Health and Access to Care<\/strong>. As noted by Anne-Sophie Joly, the president of the national collective of obesity associations<\/em>, this news is promising: "It’s a good development… these are medications that have been extensively awaited<\/em>." She highlights the urgency of the situation, emphasizing that "ten million people suffer from obesity. If you add all those with <\/em>overweight, it reaches half of the French population<\/em>."<\/p>\n The medications in question are Wegovy\u00ae<\/strong> and Mounjaro\u00ae<\/strong>, produced respectively by Danish pharmaceutical giant Novo Nordisk<\/strong> and American pharmaceutical company Eli Lilly<\/strong>. <\/p>\n Wegovy\u00ae<\/strong> contains semaglutide<\/em>, a hormone that regulates satiety<\/strong>, effectively helping individuals manage their hunger. In contrast, Mounjaro\u00ae<\/strong> combines tirzepatide<\/em>, which has demonstrated significant effects on weight loss. Both medications are analogs of GLP-1, similar to the well-known Ozempic\u00ae<\/em>, and are administered via injection in the abdominal area. They are intended for individuals struggling with overweight<\/strong>, obesity<\/strong> (defined as having a Body Mass Index of over 35), and type 2 diabetes<\/strong>.<\/p>\n As these medications gain potential approval for general practitioners, challenges still loom. Currently, the cost of Wegovy\u00ae<\/em> is extraordinarily high, priced at approximately 300 euros<\/strong> per box. Additionally, these medications are not covered by France’s health insurance<\/strong>, making them financially inaccessible for many. <\/p>\n Yannick Neuder has acknowledged the pressing need for feedback, stating that the ANSM will conduct a "phase of inquiry among prescribers to gather best practices."<\/em> This process aims to enrich data collection and share successful treatment strategies.<\/p>\n It is crucial to note that while the prospect of broader access to these medications is promising, they come with responsibilities. Medical professionals will need to intelligently assess patient profiles<\/em>, ensuring that these treatments are used safely and appropriately. <\/p>\n The potential expansion of prescription rights to GPs represents a significant shift<\/strong> in France’s public health approach. With obesity and overweight being critical health concerns, allowing general practitioners more autonomy to prescribe these medications might provide timely interventions for countless individuals. <\/p>\n Anne-Sophie Joly reinforced the collective responsibility of healthcare providers: "We need to ensure that these treatments are deployed fairly and effectively."<\/em> This statement underscores the pressing nature of the discussion around obesity treatment, as many questions remain. <\/p>\n As the government prepares to act, we can expect a robust debate to ensue regarding guidelines, regulations, and best practices for administering these powerful medications. <\/p>\n The involvement of general practitioners could serve to democratize access to treatments that have historically been available mainly through specialized care, thereby potentially reducing the stigma associated with seeking help for weight-related issues<\/em>. <\/p>\n Looking ahead, it is essential for healthcare providers, policymakers, and patients to work collectively to navigate this evolving landscape. Success requires the integration of medical research, ethical considerations, economic factors, and, most importantly, the experiences of individuals affected by obesity.<\/p>\n \n Jusqu’ici, seuls les renouvellements d’ordonnance \u00e9taient possibles.\n<\/p>\n En France, deux traitements font l’objet d’un encadrement strict. Depuis leur arriv\u00e9e sur le march\u00e9 en 2024, seuls les sp\u00e9cialistes en endocrinologie, diab\u00e9tologie ou nutrition peuvent les prescrire. La raison ? Des d\u00e9tournements \u00e0 des fins esth\u00e9tiques, li\u00e9s \u00e0 leur efficacit\u00e9 prouv\u00e9e sur la perte de poids. Mais cela pourrait changer.<\/p>\n L’Agence nationale du m\u00e9dicament (ANSM) doit lancer une proc\u00e9dure pour permettre aux m\u00e9decins g\u00e9n\u00e9ralistes de les prescrire, conform\u00e9ment \u00e0 la demande faite par Catherine Vautrin, ministre de la sant\u00e9, et Yannick Neuder, ministre charg\u00e9 de la Sant\u00e9 et de l’Acc\u00e8s aux soins. “C’est une bonne nouvelle (…) ce sont des m\u00e9dicaments<\/a> excessivement attendus” <\/em>a r\u00e9agi\u00a0Anne-Sophie Joly, pr\u00e9sidente du collectif national des associations d’ob\u00e8ses, aupr\u00e8s de nos confr\u00e8res\u00a0de franceinfo<\/a>. Avant de rappeler que “dix millions de personnes souffrent d’ob\u00e9sit\u00e9. Si vous ajoutez \u00e0 cela toutes les personnes qui souffrent de surpoids<\/a>, on arrive \u00e0 la moiti\u00e9 de la population fran\u00e7aise.” <\/em><\/p>\n Les deux\u00a0m\u00e9dicaments sont le Wegovy\u00a9, fabriqu\u00e9 par le laboratoire danois Novo Nordisk, et le Mounjaro\u00a9, produit par le\u00a0groupe pharmaceutique am\u00e9ricain Eli Lilly.\u00a0Le Wegovy\u00a9 contient du s\u00e9maglutide, une des hormones qui g\u00e8re la sati\u00e9t\u00e9<\/a>. Quant au Mounjaro\u00a9, il contient du tirz\u00e9patide, qui a d\u00e9montr\u00e9 des effets tr\u00e8s significatifs sur la perte de poids. Ces deux m\u00e9dicaments sont des\u00a0analogues du GLP-1\u00a0comme le c\u00e9l\u00e8bre Ozempic\u00ae. Ils\u00a0sont administr\u00e9s sous la forme d’une\u00a0injection dans le ventre,\u00a0dans la prise en charge du surpoids, de l’ob\u00e9sit\u00e9 (IMC sup\u00e9rieur \u00e0 35) et du diab\u00e8te de type 2<\/a>.<\/p>\n L’Agence du m\u00e9dicament doit\u00a0mener “une phase d’interrogation des prescripteurs pour pouvoir faire remonter les bonnes pratiques<\/em>“. “Nous sommes dans un recueil de donn\u00e9es, mais nous souhaitons avancer sur ce sujet, et si possible avant l’\u00e9t\u00e9”<\/em> a partag\u00e9\u00a0Yannick Neuder. A noter que ces m\u00e9dicaments co\u00fbtent cher (300 euros la bo\u00eete pour le Wegovy\u00ae) et qu’ils ne sont pas rembours\u00e9s par l’Assurance maladie.<\/p>\n<\/div>\nUnderstanding the Medications: Wegovy and Mounjaro<\/h2>\n
Challenges Ahead: Cost and Access<\/h2>\n
The Impact on Public Health<\/h2>\n